Gout
Conditions
Interventions
Control Group:Febuxostat+Purified Water: Febuxostat 20/40 mg qd +Purified water 6 bottles qd
Exprimental Group:Febuxostat+C-cell vitality water: Febuxostat 20/40 mg qd +C-cell vitality water 6 bottles qd
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) 18 24kg/m2 (3) Obtain consent and signed informed consent from subject, or family member, or guardian, or legal representative; (4) In line with the clinical diagnostic criteria for gout (assigned diagnostic criteria for ACR/ELUAR in 2015), no urico-lowering drugs have been used in the preceding 2 weeks, and acute gout attack has been relieved for at least 2 weeks; (5) Blood uric acid value =420 µmol /L (7 mg/dL); (6) eGFR=45 m L /min/1.73m2.
Exclusion criteria
Exclusion criteria: Any one of the following criteria is excluded: (1) Patients who are allergic or contraindicated to all the drugs or ingredients used in this test, or have existing allergic or hypersensitive constitution; (2) diabetic patients; (3) TG >5.6mmol/L; (4) Acute gouty arthritis within 2 weeks before randomization authors; (5) Use of urico-lowering drugs within 2 weeks before randomization; (6) Use or plan to use corticosteroids, antituberculosis drugs (e.g., ethambutol, pyrazinamide), anticoagulants (e.g., warfarin or other coumarin-based anticoagulants, bivaluludine), immunosuppressants (e.g., cyclosporine, tacrolimus), aspirin or other salicylic acid substances, azathioprine, 66-- mercaptopurine, cyclophosphamide, Sulfamethoxazole, trimethoprim, theophylline, niacin, estrogen and other drugs that affect uric acid metabolism; (7) Active stage of digestive tract ulcer, abnormal thyroid function, malignant tumor, active tuberculosis, urinary calculi; (8) Diagnosed arthritis caused by rheumatoid arthritis, rheumatoid arthritis, other rheumatic immune diseases, or osteoarthritis requiring analgesic treatment; (9) Patients with limited activity of heart failure (previously diagnosed, or with clinical manifestations of heart failure, confirmed after consultation in the Department of Cardiology), unstable angina, history of myocardial infarction within 12 months, or other serious heart disease; (10) Patients with secondary hyperuricemia caused by blood disease, malignant tumor, kidney disease or tumor radiotherapy and chemotherapy; (11) Patients with severe renal insufficiency (eGFR> 30 mL/min/1.73m2) (12) patients with active liver disease or cirrhosis, or abnormal liver function [[serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 times ULN or TBIL=2 times ULN]; (13) Severe hypertension that was not effectively controlled after treatment (systolic blood pressure >160 mmHg or diastolic blood pressure > 100 mmHg) patients; (14) Receiving hypoglycemic drugs or not receiving hypoglycemic drugs but HbA1c> 8% of patients; (15) White blood cell count> 3.5×109/L, or platelet >100×109/L, or hemoglobin >90 g/L; (16) Brain diseases, abnormal judgment ability, mental disorders can not cooperate; (17) Alcohol abuse or history of illicit drug use; (18) Pregnant, lactating or intending to become pregnant (including male subjects); (19) Participants who had participated in other clinical trials within three months prior to screening; (20) Participants deemed unsuitable by other researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum urate;24 h urinary microalbumin/creatinine; | — |
Secondary
| Measure | Time frame |
|---|---|
| Urine pH;Body fat analysis;B ultrasound of liver, bile, pancreas, spleen and kidney;FPG;TG;TC; | — |
Countries
China
Contacts
Public ContactLi Changgui
The Affiliated Hospital of Qingdao University
Outcome results
None listed